Esketamine (Spravato)
ESKETAMINE (SPRAVATO) TREATMENT GIVES NEW HOPE FOR RECOVERY FROM TREATMENT-RESISTANT DEPRESSION
WHAT IS ESKETAMINE?
Esketamine, also known by the brand name Spravato, is a prescription nasal spray used under medical supervision to treat treatment-resistant depression.
Unlike traditional antidepressants, esketamine works on different brain pathways and may begin to relieve symptoms within hours to days. It is typically used alongside a regular oral antidepressant and administered in a clinical setting to ensure safety and monitoring.
This treatment offers new hope for patients who have not responded to standard medications.
Is Esketamine Right for You?
If you’ve tried antidepressants or therapy and haven’t felt better, you’re not alone. Esketamine offers a safe, evidence-based alternative that’s helping thousands find relief.
📅 Confident and ready? Book a free 15-minute consultation directly with our Registered nurse.
✍️ Need help? Fill out our quick enquiry form and we’ll call you to help you book a nurse consultation.
Considering Referring a Patient for Esketamine?
If you’re unsure whether your patient is suitable for Esketamine, or want more information before referring, we’ve made it easy for you to connect.
📞 Prefer to speak to our Registered Nurse first? Book a quick call for clinical guidance.
📩 Submit a referral with your patient’s details and we will handle the rest.
Esketamine has demonstrated significant efficacy in treating treatment-resistant depression, with nearly 59% of patients experiencing substantial improvement within four weeks.
Who Is Eligible?
Patients who:
-
Are aged 18 or older
-
Have not responded to at least two antidepressant trials
-
Have no history of psychosis, uncontrolled hypertension, or serious cardiac/neurological conditions
Treatment Protocol
-
Induction Phase: Twice weekly for 4 weeks
-
Maintenance Phase: Weekly for 2–3 months, then taper based on clinical response
-
Supervised administration only (no take-home dosing)
-
Each session includes 2 hours of in-clinic monitoring
Monitoring & Follow-up
- Vital checks during the 120 minutes post-dose
- 2–4 psychiatric reviews in the first month
- Monthly psychiatric follow-up thereafter
Cost & Accessibility
- Session cost: $300 (includes supervision, facility fee, and documentation); (there is no Medicare rebate for the sessions)
- Medication is now PBS-subsidised, significantly reducing cost for eligible patients ($31.60 per 4 weeks)
What to Expect
-
Week 1-4: 2 sessions/week
-
Week 5-8: 1 session/week
-
Week 9 to End of Treatment: Weekly or fortnightly, with psychiatrist reviews
-
You’ll be monitored in our clinic for 2 hours after each session to check your response
ESKETAMINE (SPRAVATO) INFORMATION BOOKLET
We have gathered some information in our Esketamine Information Booklet to help you understand:
-
Who Is Eligible?
-
Treatment Protocol?
-
Monitoring & Follow-up?
-
Cost & Accessibility
-
What Is Esketamine?
-
What to Expect
-
Common Questions
-
Enquiry
-
Referral Process